Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gregory L. Shiferman Insider Profile
4 Followers
Gregory L. Shiferman, SVP, GC and Secretary at SAGE Therapeutics, holds 33.89K shares in SAGE Therapeutics (Ticker: SAGE).
Gregory L. Shiferman has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Gregory L. Shiferman's holdings
Insider Roles
SVP, GC and Secretary
Roles that Gregory L. Shiferman holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Gregory L. Shiferman
Gregory L. Shiferman's Trading History
List of latest transactions for each holding click on a transaction to see Gregory L. Shiferman's performance on stock
You May Also Like
Gregory L. Shiferman insider profile FAQ
What is the percentage of profitable transactions made by Gregory L. Shiferman?
The percentage of profitable transactions made by Gregory L. Shiferman is ―.
What is the average return per transaction made by Gregory L. Shiferman?
The average return per transaction made by Gregory L. Shiferman is ―.
What stocks does Gregory L. Shiferman hold?
Gregory L. Shiferman holds: SAGE stocks.
What was Gregory L. Shiferman’s latest transaction?
Gregory L. Shiferman latest transaction was an Uninformative Buy of ―.
What was Gregory L. Shiferman's most profitable transaction?
Gregory L. Shiferman’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Gregory L. Shiferman's role in SAGE Therapeutics?
Gregory L. Shiferman's role in SAGE Therapeutics is SVP, GC and Secretary.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.